H-AEEAc-OH.HCl (CAS 134978-97-5) - Product Overview
✨ Google Search Keywords: H-AEEAc-OH.HCl supplier, CAS 134978-97-5 peptide synthesis, aminoethoxy acetic acid HCl, chemical intermediate
Product Overview
H-AEEAc-OH.HCl, or 2-(2-Aminoethoxy)acetic acid hydrochloride, is a versatile chemical intermediate widely used in peptide synthesis and pharmaceutical research. This compound acts as a key building block for introducing aminoethoxy acetic acid groups into molecules, enabling precise modifications in drug design and biomolecular engineering. It is essential for peptide drug development, bioconjugation, and organic synthesis in academic and industrial laboratories.
Key Benefits
🔬 High Reactivity & Purity
≥98% purity (HPLC, NMR verified) ensures reliable performance in complex syntheses.
⚡️ Enhanced Solubility
Hydrochloride form improves solubility in aqueous and organic solvents for flexible reaction setups.
🧪 Versatile Functionalization
Enables site-specific modifications in peptides, antibodies, and small-molecule APIs.
🌿 Stability
Stable under standard storage conditions (room temperature, dry environment) with a shelf life of 2+ years.
Applications
Peptide Synthesis: Incorporates aminoethoxy acetic acid spacers in therapeutic peptides and antibody-drug conjugates (ADCs).
Bioconjugation: Links payloads to targeting molecules in cancer therapies and diagnostic probes.
Organic Intermediates: Serves as a precursor in synthesizing specialty chemicals and agrochemicals.
Research Reagents: Used in academic studies for molecular tagging and biochemical assays.
Pharmaceuticals: Supports development of metabolic disorder drugs and enzyme inhibitors.
Quality & Certification
✅ Purity: ≥98% (HPLC, NMR, elemental analysis)
✅ Compliance: Manufactured under ISO 9001 and GMP guidelines
✅ Safety: MSDS available; compliant with REACH and TSCA regulations
Market Trends
The global peptide synthesis market is projected to grow at 7.8% CAGR (2024–2030), driven by demand for targeted therapies. H-AEEAc-OH.HCl is critical in ADC development, a sector poised to exceed $18 billion by 2030. Asia-Pacific and North America lead procurement due to expanding biopharmaceutical R&D and CMO partnerships.
China
